TY - JOUR
T1 - Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia
T2 - A population-based study
AU - Liao, Chun Hui
AU - Chang, Chen Shu
AU - Wei, Wan Ching
AU - Chang, Shih Ni
AU - Liao, Chien Chang
AU - Lane, Hsien Yuan
AU - Sung, Fung Chang
N1 - Funding Information:
This study was supported partly by the National Science Council, Executive Yuan , Taiwan, Republic of China ( NSC 97-2625-M-039-003 ), China Medical University Hospital ( 1MS1 , DMR-98-067 and DMR-98-091 ) and Taiwan Department of Health Clinical Trial and Research Center for Excellence ( DOH99-TD-B-111-004 ) and Cancer Research Center of Excellence ( DOH99-TD-C-111-005 ).
PY - 2011/3
Y1 - 2011/3
N2 - Objective: This study investigates risks of developing diabetes mellitus (DM), hypertension, and hyperlipidemia in treating schizophrenia with first- and second-generation antipsychotics (FGA and SGA, respectively). Methods: We established two study sets, each consisting of patients with schizophrenia and without schizophrenia, from the insurance claims from 1997 to 2000. Study set I had 1631 patients taking FGA and 6524 non-schizophrenia controls; the other had 1224 patients taking SGA and 4896 controls. Controls were selected frequency matched with sex, age and the index year. All subjects were free of the studied metabolic disorders at the baseline. We measured incidences of these disorders developed by the end of 2008 in each cohort and their respective hazard ratios (HRs) for these disorders. Results: Schizophrenic patients taking FGA were older than those taking SGA. In the Cox models, significance adjusted HRs associated with SGA were 1.82 (95% confidence interval (CI) 1.30-2.55) for DM and 1.41 (95% CI 1.09-1.83) for hyperlipidemia. For those on the FGA, the risk was only significant in developing DM (HR 1.32, 95% CI 1.01-1.75). The age-specific antipsychotics-associated risks for metabolic disorders were higher in young patients than in older patients particularly for hypertension; the HRs in 10-19. years of age were 4.52 (95% CI 1.76-11.6) associated with FGA and 3.92 (95% CI 1.83-8.39) associated with SGA. Conclusions: Patients with schizophrenia on SGA have higher risk of developing metabolic disorders than those on FGA. It is likely that older patients have already gone through the age of developing these side-effects and were free of them at the baseline.
AB - Objective: This study investigates risks of developing diabetes mellitus (DM), hypertension, and hyperlipidemia in treating schizophrenia with first- and second-generation antipsychotics (FGA and SGA, respectively). Methods: We established two study sets, each consisting of patients with schizophrenia and without schizophrenia, from the insurance claims from 1997 to 2000. Study set I had 1631 patients taking FGA and 6524 non-schizophrenia controls; the other had 1224 patients taking SGA and 4896 controls. Controls were selected frequency matched with sex, age and the index year. All subjects were free of the studied metabolic disorders at the baseline. We measured incidences of these disorders developed by the end of 2008 in each cohort and their respective hazard ratios (HRs) for these disorders. Results: Schizophrenic patients taking FGA were older than those taking SGA. In the Cox models, significance adjusted HRs associated with SGA were 1.82 (95% confidence interval (CI) 1.30-2.55) for DM and 1.41 (95% CI 1.09-1.83) for hyperlipidemia. For those on the FGA, the risk was only significant in developing DM (HR 1.32, 95% CI 1.01-1.75). The age-specific antipsychotics-associated risks for metabolic disorders were higher in young patients than in older patients particularly for hypertension; the HRs in 10-19. years of age were 4.52 (95% CI 1.76-11.6) associated with FGA and 3.92 (95% CI 1.83-8.39) associated with SGA. Conclusions: Patients with schizophrenia on SGA have higher risk of developing metabolic disorders than those on FGA. It is likely that older patients have already gone through the age of developing these side-effects and were free of them at the baseline.
KW - Antipsychotics
KW - Metabolic abnormality
KW - Retrospective cohort study
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=79952039606&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952039606&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2010.12.007
DO - 10.1016/j.schres.2010.12.007
M3 - Article
C2 - 21216567
AN - SCOPUS:79952039606
SN - 0920-9964
VL - 126
SP - 110
EP - 116
JO - Schizophrenia Research
JF - Schizophrenia Research
IS - 1-3
ER -
